ACTRN12612000851864进行中（未招募）2 期
Phase II study of nilotinib plus pegylated interferon alfa-2b as first-line therapy in chronic phase chronic myeloid leukaemia aiming to maximize complete molecular response and major molecular response
Australasian Leukaemia and Lymphoma Group0 个研究点目标入组 60 人开始时间: 2012年8月13日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Post-pubertal male or female patients aged 18 years or above.
- •2.Newly diagnosed (within six months of study entry) Ph+ CML-chronic phase with a quantifiable BCR-ABL transcript
- •3.No prior therapy for CML and no other current anti-leukaemic therapies (other than prior or current treatment with hydroxyurea or anagrelide).
- •4.No signs of extramedullary leukaemia, except for hepatosplenomegaly.
- •5.Documented chronic-phase CML as defined by:
- •i. <15% blasts in both the peripheral blood and bone marrow
- •ii. <30% blasts and promyelocytes in both the peripheral blood and bone marrow
- •iii. <20% basophils in the peripheral blood
- •iv. Platelet count >100 × 10^9/L
- •6.Eastern cooperative oncology group Performance Status score less than or equal to 2
- •7.Patients must have the following laboratory values:
- •a) Potassium level > lower limit of normal (LLN)
- •b) Calcium (corrected for serum albumin) > LLN
- •c) Magnesium level > LLN
- •d) Phosphorus > LLN
- •e) Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) < 2.5 × upper limit of normal (ULN) or < 5.0 × ULN if considered due to tumour
- •f) Alkaline phosphatase (ALP) < 2.5 × ULN unless considered due to tumour
- •g) Bilirubin < 1.5 × ULN unless due to Gilbert’s syndrome
- •h) Creatinine < 1.5 × ULN
- •i) Amylase and lipase < 1.5 × ULN
- •8.a) Female patients of childbearing potential must have a negative serum pregnancy test within one week prior to study entry OR have been amenorrhoeic for at least 12 months.
- •b) All patients of reproductive potential must agree to use birth control for the duration of the study. This is only required for as long as the patient has reproductive potential. The type of birth control is a decision which should be made between the treating clinician and the patient.
- •9.Life expectancy of more than 12 months.
- •10.Patient has given written, informed consent to participate in the study
排除标准
- •1.Patients who have previously received radiotherapy to >25% of their bone marrow.
- •2.Patients who have undergone major surgery within the 4 weeks prior to study entry or have not recovered from earlier surgery.
- •3.Impaired cardiac function, including any of the following:
- •a.Inability to monitor the QT/QTcorrected interval on electrocardiogram (ECG)
- •b.Long QT syndrome or a known family history of long QT syndrome.
- •c.Resting bradycardia (<50 beats per minute) suspected to be secondary to cardiac pathology
- •d.Qt interval corrected (QTc) > 450 msec on baseline ECG (using the QTcF formula). If QTcF >450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc
- •e.Myocardial infarction within 12 months prior to starting study
- •f.Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension)
- •g.History of or presence of clinically significant ventricular or atrial tachyarrhythmias
- •4.Treatment with agents (other than warfarin) that prolong QT interval or inhibit CYP3A4, unless judged to be clinically essential.
- •5.Another primary malignant disease, except for such conditions that do not currently require treatment, lesions that can be or had been completely excised (eg Skin Cancers) and neoplasms that does not significantly affect long term survival of the patient
- •6.Significantly impaired gastrointestinal (GI) function or GI disease that may alter nilotinib absorption.
- •7.Other concurrent uncontrolled medical conditions (e.g. uncontrolled diabetes, active or uncontrolled infections, acute or chronic liver and renal disease) that could cause unacceptable safety risks or compromise compliance with the protocol.
- •8.History of confirmed acute or chronic pancreatitis.
- •9.Cytopathologically confirmed central nervous system (CNS) infiltration. [In the absence of suspicion of CNS involvement, lumbar puncture is not required.]
- •10.Patients unwilling or unable to comply with protocol and patients with a history of noncompliance or inability to grant informed consent.
- •11.Known diagnosis of human immunodeficiency virus (HIV) infection.
- •12.Prior allogeneic stem cell transplantation
- •13.Patients who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control. Male and female patients of childbearing potential must agree to employ an effective method of birth control throughout the study and for up to 3 months following discontinuation of study drug; The type of birth control is a decision which should be made between the treating clinician and the patient
- •14.Known history of uncontrolled depression or any other psychiatric disease likely to be exacerbated by study treatment. A formal psychiatric assessment at baseline is not required.
- •15.Current participation in another therapeutic clinical trial (participation in clinical trials that do not involve active interventions is not an exclusion for the study.)
- •16.Previous adverse reaction to the trial drug/s
研究者
相似试验
进行中（未招募）
1 期
Phase II study of nilotinib efficacy in Pigmented Villo-Nodular Synovitis / Tenosynovial Giant Cell Tumor (PVNS / TGCT) - PVNSPatients with inoperable Pigmented Villonodular Synovitis / Tenosynovial Giant Cell Tumour (PVNS/TGCT)MedDRA version: 12.1 Level: LLT Classification code 10042875 Term: Synovitis villonodularEUCTR2010-018869-29-FRCENTRE LEON BERARD56
进行中（未招募）
1 期
Phase II study of nilotinib efficacy in Pigmented Villo-Nodular Synovitis / Tenosynovial Giant Cell Tumor (PVNS / TGCT) - PVNSEUCTR2010-018869-29-NLCENTRE LEON BERARD56
进行中（未招募）
1 期
Study of nilotinib efficacy in Pigmented Villo-Nodular Synovitis / Tenosynovial Giant Cell TumorPatients with inoperable Pigmented Villonodular Synovitis / Tenosynovial Giant Cell Tumour (PVNS/TGCT)MedDRA version: 14.0 Level: LLT Classification code 10042875 Term: Synovitis villonodular System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-018869-29-GBCentre Leon-Berard56
进行中（未招募）
1 期
A Phase II Trial of Nilotinib in the Treatment of Patients with c-KIT Mutated Advanced Acral and Mucosal Melanoma (NICAM) - Nilotinib in the Treatment of c-KIT Mutated Melanoma (NICAM)c-KIT mutated advanced acral or mucosal melanomaMedDRA version: 10 Level: LLT Classification code 10025654 Term: Malignant melanoma of sites other than skinMedDRA version: 10 Level: LLT Classification code 10000583 Term: Acral lentiginous melanomaEUCTR2009-012945-49-GBRoyal Marsden Hosptial Foundation Trust29
进行中（未招募）
1 期
PHASE II STUDY OF NILOTINIB EFFICACY IN PIGMENTED VILLO-NODULAR SYNOVITIS/ TENOSYNOVIAL GIANT CELL TUMOUR (PVNS/TGCT) - NDPigmented villonodular synovitis (PVNS), also known as tenosynovial giant cell tumour (TGCT)MedDRA version: 9.1Level: LLTClassification code 10042875EUCTR2010-018869-29-ITISTITUTO NAZIONALE PER LA CURA TUMORI56